Alnylam Pharmaceuticals, Inc. Website

Alnylam Pharmaceuticals, Inc.

NasdaqGS-ALNY

Basic

  • Market Cap

    $29.94B

  • EV

    $30.25B

  • Shares Out

    126.49M

  • Revenue

    $2,003.34M

  • Employees

    2,100

Margins

  • Gross

    83.95%

  • EBITDA

    -6.1%

  • Operating

    -8.78%

  • Pre-Tax

    -16.21%

  • Net

    -16.58%

  • FCF

    6.38%

Returns (5Yr Avg)

  • ROA

    -28.77%

  • ROTA

    -86.73%

  • ROE

    -86.73%

  • ROCE

    -30.17%

  • ROIC

    -83.18%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $254.83

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $2,371.28M

  • Net Debt

    $313.02M

  • Debt/Equity

    -12.24

  • EBIT/Interest

    -1.38

Growth (CAGR)

  • Rev 3Yr

    51.96%

  • Rev 5Yr

    87.56%

  • Rev 10Yr

    49.14%

  • Dil EPS 3Yr

    -29.48%

  • Dil EPS 5Yr

    -19.57%

  • Dil EPS 10Yr

    -6.52%

  • Rev Fwd 2Yr

    12.25%

  • EBITDA Fwd 2Yr

  • EPS Fwd 2Yr

  • EPS LT Growth Est

    29%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

219.8

492.9

844.3

1,037.4

1,828.3

2,003.3

Total Revenues % Chg.

193.4%

124.3%

71.3%

22.9%

76.2%

75.2%

Cost of Goods Sold, Total

25.1

78.1

140.1

168.8

310.4

321.5

Gross Profit

194.7

414.8

704.1

868.6

1,517.9

1,681.8

Selling General & Admin Expenses, Total

533.7

588.4

620.6

770.7

795.6

822.8

R&D Expenses

600.5

654.8

792.2

883

1,004.4

1,034.8

Other Operating Expenses, Total

1,134.1

1,243.2

1,412.8

1,653.7

1,800.1

1,857.6

Operating Income

-939.4

-828.4

-708.7

-785.1

-282.2

-175.8

Interest Expense, Total

-84.5

-143

-156

-121.2

-127.5

Interest And Investment Income

33.4

11.8

1.6

24.8

95.6

106.6

Net Interest Expenses

33.4

-72.7

-141.4

-131.2

-25.7

-21

Other Non Operating Income (Expenses)

9.4

-8.5

-57.7

-100.9

-108.7

-113.4

EBT, Excl. Unusual Items

-896.5

-909.6

-907.8

-1,017.1

-416.6

-310.1

Gain (Loss) On Sale Of Investments

11.3

54

55.7

-33.3

-16.9

-14.6

In Process R&D Expenses

Other Unusual Items

-76.6

EBT, Incl. Unusual Items

-885.3

-855.6

-852.1

-1,127

-433.5

-324.7

Income Tax Expense

0.9

2.7

0.7

4.2

6.7

7.3

Earnings From Continuing Operations

-886.1

-858.3

-852.8

-1,131.2

-440.2

-332.1

Net Income

-886.1

-858.3

-852.8

-1,131.2

-440.2

-332.1

Net Income to Common Incl Extra Items

-886.1

-858.3

-852.8

-1,131.2

-440.2

-332.1

Net Income to Common Excl. Extra Items

-886.1

-858.3

-852.8

-1,131.2

-440.2

-332.1

Total Shares Outstanding

112.2

116.4

120.2

123.9

125.8

126.5

Weighted Avg. Shares Outstanding

109.3

115

118.5

121.7

124.9

125.4

Weighted Avg. Shares Outstanding Dil

109.3

115

118.5

121.7

124.9

125.4

EPS

-8.1

-7.5

-7.2

-9.3

-3.5

-2.6

EPS Diluted

-8.1

-7.5

-7.2

-9.3

-3.5

-2.6

EBITDA

-922.3

-793.7

-661.1

-740.6

-228.1

-122.3

Effective Tax Rate

-0.1%

-0.3%

-0.1%

-0.4%

-1.6%

-2.3%